

---

**Supplementary information**

---

**Seasonal coronavirus protective immunity  
is short-lasting**

---

In the format provided by the  
authors and unedited

# Supplementary Materials for

## Seasonal coronavirus protective immunity is short-lasting

NMED-BC105995A

Arthur W. D. Edridge<sup>1</sup>, Joanna Kaczorowska<sup>1</sup>, Alexis C. R. Hoste<sup>2</sup>, Margreet Bakker<sup>1</sup>, Michelle Klein<sup>1</sup>, Katherine Loens<sup>3,4</sup>, Maarten F. Jebbink<sup>1</sup>, Amy Matser<sup>5</sup>, Cormac M. Kinsella<sup>1</sup>, Paloma Rueda<sup>2</sup>, Margareta Ieven<sup>3</sup>, Herman Goossens<sup>3,4</sup>, Maria Prins<sup>5,6</sup>, Patricia Sastre<sup>2</sup>, Martin Deijis<sup>1</sup>, Lia van der Hoek<sup>1,\*</sup>

Correspondence to: [c.m.vanderhoek@amc.uva.nl](mailto:c.m.vanderhoek@amc.uva.nl)



1. Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
2. INGENASA, Inmunología y Genética Aplicada S. A., Av. de la Institución Libre de Enseñanza, 39, 28037 Madrid, Spain
3. Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium;
4. Department of Microbiology, University Hospital Antwerp, Edegem, Belgium
5. Department of Infectious Diseases, Public Health Service of Amsterdam, Nieuwe Achtergracht 100, 1018 WT Amsterdam The Netherlands.
6. Amsterdam UMC, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.

### This PDF file includes:



Supplementary Fig. 1

Supplementary Table 1 – 4



**Supplementary Fig. 1. Antibody reactivity to NcT of HCoV-NL63, HCoV-229E, HCoV-OC43, HCoV-HKU1, and full N of SARS-CoV-2.** Red: normalized optical density (OD) for HCoV-NL63, blue: HCoV-229E, green: HCoV-OC43, purple: HCoV-HKU1, orange: SARS-CoV-2, gray: measles virus. Error-bars show standard deviations from two or three replicates. In black font and underlined: OD fold rises  $\geq 1.40$  marking an infection for the indicated HCoV. In grey font: OD fold rises  $\geq 1.40$  classified as cross-reactivity or when no differentiation could be made between the infecting and the cross-reactive HCoV (when the difference in fold change was  $< 10\%$ ).





Supplementary Fig. 1 continued



Supplementary Fig. 1 continued




**Supplementary Fig. 1 continued**






Supplementary Fig. 1 continued

Subject 09



Subject 10



**Supplementary Table 1. Identity between coronaviruses for full N-protein and Nt-protein**

<b>FULL N-protein</b>	<b>HKU1</b>	<b>OC43</b>	<b>SARS-CoV-2</b>	<b>229E</b>	<b>NL63</b>	<b>Accession</b>
<b>HKU1</b>	100%	-	-	-	-	ADN03343.1
<b>OC43</b>	<b>65.69%*</b>	100%	-	-	-	AAR01019.1
<b>SARS-CoV-2</b>	32.55%	34.14%	100%	-	-	YP_009724397.2
<b>229E</b>	26.26%	23.65%	23.51%	100%	-	NP_073556.1
<b>NL63</b>	24.44%	24%	25.87%	<b>46.21%</b>	100%	YP_003771.1
<b>Nt in this study</b>						
<b>HKU1</b>	100%					
<b>OC43</b>	<b>49.59%</b>	100%				
<b>SARS-CoV-2</b>	<20%	<20%	100%			
<b>229E</b>	<20%	<20%	<20%	100%		
<b>NL63</b>	<20%	<20%	<20%	<b>41.77%</b>	100%	

\* Full N-protein identity HCoV-OC43 vs HCoV-HKU1: 66%, and Nt identity 50%, so Nt as antigen in ELISA is more specific; Full N-protein identity HCoV-NL63 vs HCoV-229E: 46%, and Nt identity 42%, so Nt as antigen in ELISA is more specific

**Supplementary Table 2. Within species diversity for the Spike protein and the N-protein.** An identity matrix was made from representatives of all variants described in literature. Presented in the table is the identity shared between the most divergent strains within a seasonal coronavirus species.

**Spike protein**

Intraspecies variation HCoV-NL63:	97.01 % identity
Intraspecies variation HCoV-229E:	94.75 % identity
Intraspecies variation HCoV-OC43:	94.17 % identity
Intraspecies variation HCoV-HKU1:	84.66 % identity

**N-protein**

Intraspecies variation HCoV-NL63:	97.34 % identity
Intraspecies variation HCoV-229E:	95.39 % identity
Intraspecies variation HCoV-OC43:	97.09 % identity
Intraspecies variation HCoV-HKU1:	90.02 % identity



**Supplementary Table 3. Cross-reactivity of antibodies within genera.** Results of the anti-NcT ELISA for each seasonal coronavirus on paired sera of the RT-PCR confirmed coronavirus infections. In grey: blocks where cross reactivity within genera is shown. In bold: match between antibody fold change and RT-PCR of the same HCoV.

PCR positive	Antibody rise (OD fold change >1.4)			
	NL63	229E	OC43	HKU1
NL63 (n = 11)	<b>11 (100%)</b>	4 (36%)	0 (0%)	0 (0%)
229E (n = 16)	9 (56%)	<b>13 (81%)</b>	0 (0%)	1 (6%)
OC43 (n = 14)	0 (0%)	0 (0%)	<b>10 (71%)</b>	2 (14%)
HKU1 (n = 18)	1 (6%)	1 (6%)	1 (6%)	<b>4 (22%)</b>

**Supplementary Table 4. Self-reported symptoms since previous visit**

		No virus (n=398)	Any virus (n=93)	NL63 (n=23)	229E (n=37)	OC43 (n=29)	HKU1 (N=10)
Any symptom*	n (%) p-value**	69 (17.3%)	<b>26 (28.0%)</b> <b>0.028</b>	<b>10 (43.5%)</b> <b>0.006</b>	9 (24.3%) 0.396	6 (20.7%) 0.811	3 (30.0%) 0.414
Fever ( >38 °C, > 3 days)	n (%) p-value	23 (5.8%)	<b>12 (12.9%)</b> <b>0.024</b>	<b>6 (26.1%)</b> <b>0.003</b>	4 (10.8%) 0.325	2 (6.9%) 1.000	2 (20.0%) 0.149
Fatigue	n (%) p-value	20 (5.0%)	4 (4.3%) 1.000	2 (8.7%) 0.314	2 (5.4%) 0.701	0 (0.0%) 0.386	1 (10.0%) 0.398
Cough	n (%) p-value	25 (6.3%)	8 (8.6%) 0.489	4 (17.4%) 0.061	3 (8.1%) 0.730	0 (0.0%) 0.246	2 (20.0%) 0.141
Sore throat	n (%) p-value	10 (2.5%)	5 (5.4%) 0.175	2 (8.7%) 0.154	2 (5.4%) 0.316	1 (3.4%) 0.605	0 (0.0%) 1.000
Headache	n (%) p-value	5 (1.3%)	4 (4.3%) 0.070	1 (4.3%) 0.355	2 (5.4%) 0.143	1 (3.4%) 0.425	0 (0.0%) 1.000
Dyspnoea	n (%) p-value	16 (4.0%)	5 (5.4%) 0.570	1 (4.3%) 1.000	3 (8.1%) 0.206	0 (0.0%) 0.627	2 (20.0%) 0.064
Myalgia	n (%) p-value	12 (3.0%)	5 (5.4%) 0.339	1 (4.3%) 0.566	1 (2.7%) 1.000	3 (10.3) 0.072	0 (0.0%) 1.000
Nausea	n (%) p-value	5 (1.3%)	2 (2.2%) 0.622	0 (0.0%) 1.000	1 (2.7%) 0.426	0 (0.0%) 1.000	1 (10.0%) 0.135
Diarrhea	n (%) p-value	5 (1.3%)	4 (4.3%) 0.070	0 (0.0%) 1.000	1 (2.7%) 0.510	2 (6.9%) 0.094	1 (10.0%) 0.153

\* Methods of data collection: During the cohort visit, participants were asked whether they had experienced the following symptoms since their last visit: fever (temperature >38 °C for at least 3 days), fatigue, cough, sore throat, headache, dyspnea, myalgia, nausea, or diarrhea.

\*\* p-value results from Fisher's exact test. Comparison group = 'no virus (n=398)'